PROTALIX BIOTHERAPEUTICS, INC. Financials Protalix BioTherapeutics, Inc.
Equities
PLX
US74365A3095
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.14 USD | -2.56% |
|
+3.64% | -35.96% |
| May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
| May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 48.67 | 118.5 | 37.89 | 69.41 | 129.9 | 83.58 | - | - |
| Enterprise Value (EV) 1 | 48.67 | 118.5 | 37.89 | 69.41 | 129.9 | 83.58 | 83.58 | 83.58 |
| P/E ratio | -2.67 x | -16.5 x | -1.34 x | -4.42 x | 19.8 x | 9.5 x | 1.81 x | 1.01 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.07 x | 7.3 x | 0.99 x | 1.46 x | 1.98 x | 1.59 x | 0.82 x | 0.5 x |
| EV / Revenue | 3.07 x | 7.3 x | 0.99 x | 1.46 x | 1.98 x | 1.59 x | 0.82 x | 0.5 x |
| EV / EBITDA | -5,348,285 x | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 14,838 | 32,643 | 45,557 | 50,666 | 72,952 | 73,316 | - | - |
| Reference price 2 | 3.280 | 3.630 | 0.8317 | 1.370 | 1.780 | 1.140 | 1.140 | 1.140 |
| Announcement Date | 3/12/20 | 3/30/21 | 3/31/22 | 2/27/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15.87 | 16.24 | 38.35 | 47.64 | 65.49 | 52.7 | 101.4 | 167.2 |
| EBITDA | -9.1 | - | - | - | - | - | - | - |
| EBIT 1 | -10.72 | 2.71 | -20.46 | -13.01 | 10.46 | 8.742 | 54.79 | 105.5 |
| Operating Margin | -67.55% | 16.69% | -53.36% | -27.32% | 15.97% | 16.59% | 54.04% | 63.13% |
| Earnings before Tax (EBT) 1 | -18.28 | -6.523 | -27.58 | -14.4 | 8.566 | 8.752 | 54.59 | 105.1 |
| Net income 1 | -18.28 | -6.523 | -27.58 | -14.93 | 8.312 | 8.89 | 54.59 | 99.89 |
| Net margin | -115.19% | -40.18% | -71.92% | -31.33% | 12.69% | 16.87% | 53.84% | 59.74% |
| EPS 2 | -1.230 | -0.2200 | -0.6200 | -0.3100 | 0.0900 | 0.1200 | 0.6300 | 1.130 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/30/21 | 3/31/22 | 2/27/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.549 | - | 8.753 | 14.18 | 8.617 | - | 35.08 | 10.34 | 10.49 | 3.677 | 12.5 | 16.3 | 20.2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.706 | - | -5.524 | -3.125 | -2.495 | - | 20.42 | -1.887 | -5.615 | - | 1.734 | 4.388 | 7.476 |
| Operating Margin | -66.74% | - | -63.11% | -22.03% | -28.95% | - | 58.22% | -18.24% | -53.55% | - | 13.87% | 26.92% | 37.01% |
| Earnings before Tax (EBT) 1 | -6.667 | - | -5.334 | -3.567 | -3.21 | - | 19.65 | -1.719 | -6.426 | - | 1.834 | 4.288 | 7.526 |
| Net income 1 | -6.667 | -2.286 | -5.334 | -3.567 | -3.74 | -3.131 | 19.34 | -1.852 | -6.044 | - | 1.834 | 4.288 | 7.526 |
| Net margin | -77.99% | - | -60.94% | -25.15% | -43.4% | - | 55.14% | -17.9% | -57.64% | - | 14.67% | 26.31% | 37.26% |
| EPS 2 | -0.1400 | -0.0500 | -0.1100 | -0.0700 | -0.0700 | -0.0500 | 0.2100 | -0.0300 | -0.0700 | -0.0600 | 0.0200 | 0.0600 | 0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 2/27/23 | 5/4/23 | 8/7/23 | 11/6/23 | 3/14/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.63 | - | - | - | - | - | - | - |
| Capex / Sales | 3.95% | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/30/21 | 3/31/22 | 2/27/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.14
USD
Average target price
12
USD
Spread / Average Target
+952.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.96% | 83.58M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- PLX Stock
- Financials Protalix BioTherapeutics, Inc.
